May 19, 2026 ScienceFinding the molecular switches behind new infectious diseases ShareThe majority of emerging infectious diseases are caused by pathogens that jump from animals to humans, such as Ebola, HIV, flu and Covid-19. Professor Clare Bryant at the University of Cambridge is using Co-Scientist to hunt for the molecular switches that cause severe diseases, like sepsis, in humans when pathogens leap between species, and find new approaches to prevent this happening.Testing Co-Scientist, Bryant fed it a summary of one of her grant proposals studying flu in birds and humans outlining her lab’s research questions. The tool generated and ranked a set of promising hypotheses — some she'd already considered, some she hadn't. The unfamiliar ones were the most thought-provoking.When the grant was funded, Bryant fed in the full, detailed proposal. Later, reading through the output on a train to Brussels, she had an "a-ha!" moment: Co-Scientist had prioritised a protein that hadn’t been on her radar, connected to several signalling pathways she was already interested in. She spent the rest of the week itching to give it more data.Back at her lab, she added unpublished material, kept confidential within Co-Scientist. With each back-and-forth, the hypotheses sharpened, moving from candidate proteins down to the specific amino acids her lab could focus its experiments on.Bryant's team is now building cell lines containing the amino acid mutations to test the refined hypotheses. To get to the point of identifying precise amino acids would normally have taken two to three years of experimental work. But her lab is now on track to complete it in six months, she says, if the work with Co-Scientist has led them to the right targets.Co-Scientist pulls together the entire published literature and online resources to help me ask better questions. It catches what I'd miss in a data-rich field and helps me prioritise, so my team can focus on answering the right questions in the lab. Professor Clare Bryant, University of Cambridge Related postsCo-Scientist: A multi-agent AI partner to accelerate researchMay 2026Science Learn more Uncovering repurposed medicines to fight liver fibrosisMay 2026Science Learn more Uniting biological toolkits for a new approach to ALSMay 2026Science Learn more Accelerating discovery of liver disease mechanismsMay 2026Science Learn more Opening new paths in aging researchMay 2026Science Learn more Fast-tracking genetic leads to reverse cellular agingMay 2026Science Learn more
Co-Scientist
Fast-tracking infectious disease research
Related
ResearchLearning When to Trust via Selective Context Preference Optimization
Language models increasingly condition their answers on external signals, and a single misleading one can turn a correct answer wrong. The obvious remedy, training models to resist such signals, hides a failure mode: a model that ignores all context looks robust yet is useless when the context is worth trusting. We recast the problem as selective trust and introduce MIST, a human-annotated benchmark that renders each reasoning item under four matched conditions (clean, misleading, correct-context, and irrelevant-context), together with SC2W, a paired metric counting how often a misle
Learning When to Trust via Selective Context Preference Optimization
Language models increasingly condition their answers on external signals, and a single misleading one can turn a correct answer wrong. The obvious remedy, tr...
ResearchTracing the Heart: An Evidence-Linked Pipeline for Heart-Failure Feature Engineering
Electronic health record (EHR) feature engineering is a major bottleneck in clinical research and AI, accounting for 39-45% of data scientists' workload. This is especially pronounced in heart failure, which affects an estimated 6.7 million U.S. adults and requires integrating fragmented EHR data with disease-specific, guideline-based clinical reasoning. Existing rule-based and large language model (LLM)-based approaches offer only partial automation with limited maintainability and evidence traceability. We developed the Nimblemind Multi-Agent System (nMAS), an evidence-linked, rubr